Associations between Biomarkers of Complement Activation, Galactose-Deficient IgA1 Antibody and the Updated Oxford Pathology Classification of IgA Nephropathy

被引:7
作者
Juan, Yun-Ting [1 ]
Chiang, Wen-Chih [2 ]
Lin, Wei-Chou [3 ]
Yang, Cheng-Wen [1 ]
Chou, San-Fang [4 ]
Hung, Ruo-Wei [1 ]
Chiu, Yen-Ling [1 ,4 ,5 ,6 ,7 ]
机构
[1] Far Eastern Mem Hosp, Dept Nephrol, New Taipei 220, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Med, Div Nephrol, Taipei 100, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Pathol, Taipei 100, Taiwan
[4] Far Eastern Mem Hosp, Dept Med Res, New Taipei 220, Taiwan
[5] Yuan Ze Univ, Grad Inst Med, Taoyuan 320, Taiwan
[6] Yuan Ze Univ, Grad Program Biomed Informat, Taoyuan 320, Taiwan
[7] Natl Taiwan Univ, Grad Inst Clin Med, Coll Med, Taipei 100, Taiwan
关键词
complement C5a; factor Ba; galactose-deficient IgA1; IgA nephropathy; Oxford classification;
D O I
10.3390/jcm11144231
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Our prior study indicates a close relationship between alternative complement pathway activation, galactose-deficient IgA1 (Gd-IgA1) concentration and clinical severity of IgA nephropathy (IgAN). Nonetheless, the relationship between complement factors and the updated Oxford classification of IgAN remains unclear. This study enrolled eighty-four previously untreated, biopsy-diagnosed IgAN patients. The clinical and laboratory findings were collected at the time of biopsy. Plasma levels of complement factor C5a, factor Ba and Gd-IgA1 were measured and analyzed. It was found that the levels of proteinuria positively correlated with the updated Oxford classification of mesangial hypercellularity (M), endocapillary hypercellularity (E), tubular atrophy/interstitial fibrosis (T) and crescents (C). In addition, plasma Gd-IgA1 titer was significantly elevated in IgAN patients with tubular atrophy/interstitial fibrosis (T). In separate multivariable logistic regression models, both Gd-IgA1 and factor Ba independently predict higher T scores. The results indicate that both the levels of Gd-IgA1 antibody and biomarkers of the alternative complement pathway activation reflect the Oxford classification of IgAN. Whether these biomarkers can be used to guide therapeutic decisions requires further study.
引用
收藏
页数:11
相关论文
共 24 条
[1]   Significance of serum galactose deficient IgA1 as a potential biomarker for IgA nephropathy: A case control study [J].
Bagchi, Soumita ;
Lingaiah, Raghavendra ;
Mani, Kalaivani ;
Barwad, Adarsh ;
Singh, Geetika ;
Balooni, Veena ;
Bhowmik, Dipankar ;
Agarwal, Sanjay Kumar .
PLOS ONE, 2019, 14 (03)
[2]   Evaluating a New International Risk-Prediction Tool in IgA Nephropathy [J].
Barbour, Sean J. ;
Coppo, Rosanna ;
Zhang, Hong ;
Liu, Zhi-Hong ;
Suzuki, Yusuke ;
Matsuzaki, Keiichi ;
Katafuchi, Ritsuko ;
Er, Lee ;
Espino-Hernandez, Gabriela ;
Kim, S. Joseph ;
Reich, Heather N. ;
Feehally, John ;
Cattran, Daniel C. ;
Russo, M. L. ;
Troyanov, S. ;
Cook, H. T. ;
Roberts, I. ;
Tesar, V. ;
Maixnerova, D. ;
Lundberg, S. ;
Gesualdo, L. ;
Emma, F. ;
Fuiano, L. ;
Beltrame, G. ;
Rollino, C. ;
Amore, A. ;
Camilla, R. ;
Peruzzi, L. ;
Praga, M. ;
Feriozzi, S. ;
Polci, R. ;
Segoloni, G. ;
Colla, L. ;
Pani, A. ;
Piras, D. ;
Angioi, A. ;
Cancarini, G. ;
Ravera, S. ;
Durlik, M. ;
Moggia, E. ;
Ballarin, J. ;
Di Giulio, S. ;
Pugliese, F. ;
Serriello, I. ;
Caliskan, Y. ;
Sever, M. ;
Kilicaslan, I. ;
Locatelli, F. ;
Del Vecchio, L. ;
Wetzels, J. F. M. .
JAMA INTERNAL MEDICINE, 2019, 179 (07) :942-952
[3]  
BERGER J, 1987, SEMIN NEPHROL, V7, P277
[4]   Natural history of primary IgA nephropathy [J].
Berthoux, Franpis C. ;
Whey, Heshom ;
Aflani, Aida .
SEMINARS IN NEPHROLOGY, 2008, 28 (01) :4-9
[5]   Oxidative Stress and Galactose-Deficient IgA1 as Markers of Progression in IgA Nephropathy [J].
Camilla, Roberta ;
Suzuki, Hitoshi ;
Dapra, Valentina ;
Loiacono, Elisa ;
Peruzzi, Licia ;
Amore, Alessandro ;
Ghiggeri, Gian Marco ;
Mazzucco, Gianna ;
Scolari, Francesco ;
Gharavi, Ali G. ;
Appel, Gerald B. ;
Troyanov, Stephan ;
Novak, Jan ;
Julian, Bruce A. ;
Coppo, Rosanna .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 6 (08) :1903-1911
[6]  
Cattran D.C., 2009, KIDNEY INT, V76, P534, DOI [10.1038/ki.2009.243, DOI 10.1038/KI.2009.243]
[7]   Alternative Complement Pathway Is Activated and Associated with Galactose-Deficient IgA1 Antibody in IgA Nephropathy Patients [J].
Chiu, Yen-Ling ;
Lin, Wei-Chou ;
Shu, Kai-Hsiang ;
Fang, Yi-Wen ;
Chang, Fan-Chi ;
Chou, Yu-Hsiang ;
Wu, Ching-Fang ;
Chiang, Wen-Chih ;
Lin, Shuei-Liong ;
Chen, Yung-Ming ;
Wu, Ming-Shiou .
FRONTIERS IN IMMUNOLOGY, 2021, 12
[8]   IgA nephropathy: new insights into the role of complement [J].
Floege, Jurgen ;
Daha, Mohamed R. .
KIDNEY INTERNATIONAL, 2018, 94 (01) :16-18
[9]   Clinical Relevance of Serum Galactose Deficient IgA1 in Patients with IgA Nephropathy [J].
Kim, Jin Sug ;
Hwang, Hyeon Seok ;
Lee, Sang Ho ;
Kim, Yang Gyun ;
Moon, Ju-Young ;
Kong, Ji Yoon ;
Jeong, Kyung Hwan .
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (11)
[10]   Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy [J].
Lafayette, Richard A. ;
Rovin, Brad H. ;
Reich, Heather N. ;
Tumlin, James A. ;
Floege, Juergen ;
Barratt, Jonathan .
KIDNEY INTERNATIONAL REPORTS, 2020, 5 (11) :2032-2041